Analysis Finds Efficiencies, Savings of Using a Single Bispecific for DLBCL and FL

Why It Matters

Consolidating to a single bispecific streamlines oncology workflows, cutting costs and freeing staff for patient care, which could reshape formulary decisions across the U.S. market.

Key Takeaways

• Single bispecific cuts onboarding time across practices
• Community clinics save $278k, $2.6k per patient
• Academic centers could save over $1.2M, $11k per patient
• 74% report reduced manufacturer setup burden
• Study limited by self‑reported data and sponsor bias

Pulse Analysis

The rise of bispecific antibodies has added therapeutic depth to non‑Hodgkin lymphoma treatment, yet the proliferation of single‑indication products creates hidden operational costs. Each agent demands separate training, distinct payer contracts, and dedicated inventory, which strains both community and academic oncology clinics. By focusing on epcoritamab’s subcutaneous delivery and dual‑indication label, the analysis isolates a scenario where one product can replace multiple regimens, offering a clearer path to efficiency in an increasingly complex drug landscape.

Quantitative modeling shows that a typical community practice treating 100 patients could reclaim 3,110 staff hours and generate $278,013 in time‑value savings, a figure that more than doubles to $525,600 when bulk‑purchase discounts and reduced drug waste are factored in. Academic institutions, with larger staffing layers and more intricate pharmacy workflows, stand to gain even more—projected total savings exceed $1.2 million, translating to roughly $11,400 per patient. The most consistent benefit reported by 74% of surveyed clinicians was a smoother onboarding process, while 67% noted streamlined pharmacy and P&T committee preparation.

While the data underscore a compelling business case, the study’s reliance on self‑reported surveys and its funding by the drug’s manufacturer temper the conclusions. Nevertheless, the potential to lower overhead, improve staff allocation, and enhance patient throughput makes a strong argument for formulary committees to prioritize dual‑indication bispecifics. As more agents seek FDA approval, future research should validate these early savings across multiple years and diverse practice settings, guiding sustainable adoption strategies in oncology care.